Skip to main
GRAL
GRAL logo

GRAIL Inc (GRAL) Stock Forecast & Price Target

GRAIL Inc (GRAL) Analyst Ratings

Based on 3 analyst ratings
Buy
Strong Buy 67%
Buy 0%
Hold 33%
Sell 0%
Strong Sell 0%

Bulls say

GRAIL Inc has demonstrated a significant stock appreciation of nearly 90% over the past month, highlighting increasing investor confidence driven by promising data from the PATHFINDER 2 trial. The company's multi-cancer early detection blood test addresses a substantial total addressable market (TAM) in both the US and UK, with projections indicating potential opportunities of approximately $3.7 billion by 2026 and growing to $4.0 billion by 2035. Additionally, GRAIL's strategic partnerships and improved outlook following the recent ESMO data readout contribute to a positive perspective on future growth, despite existing uncertainties regarding regulatory approvals and Medicare reimbursement.

Bears say

GRAIL Inc. has consistently reported significant net losses since its inception and expects these losses to persist as it continues clinical studies and seeks necessary regulatory approvals. The company faces several risks, including potential delays in government reimbursement processes and increasing competition from established diagnostics firms, which may hinder its market adoption of the multi-cancer early detection test. Additionally, high selling, general, and administrative expenses could further strain GRAIL's financial resources, particularly if the company fails to secure additional financing for commercialization efforts.

GRAIL Inc (GRAL) has been analyzed by 3 analysts, with a consensus rating of Buy. 67% of analysts recommend a Strong Buy, 0% recommend Buy, 33% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of GRAIL Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About GRAIL Inc (GRAL) Forecast

Analysts have given GRAIL Inc (GRAL) a Buy based on their latest research and market trends.

According to 3 analysts, GRAIL Inc (GRAL) has a Buy consensus rating as of Dec 19, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $105, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $105, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

GRAIL Inc (GRAL)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.